Tumor-Specific Expression of Organic Anion-Transporting Polypeptides: Transporters as Novel Targets for Cancer Therapy
Open Access
- 3 February 2013
- journal article
- review article
- Published by Hindawi Limited in Journal of Drug Delivery
- Vol. 2013, 1-12
- https://doi.org/10.1155/2013/863539
Abstract
Members of the organic anion transporter family (OATP) mediate the transmembrane uptake of clinical important drugs and hormones thereby affecting drug disposition and tissue penetration. Particularly OATP subfamily 1 is known to mediate the cellular uptake of anticancer drugs (e.g., methotrexate, derivatives of taxol and camptothecin, flavopiridol, and imatinib). Tissue-specific expression was shown for OATP1B1/OATP1B3 in liver, OATP4C1 in kidney, and OATP6A1 in testis, while other OATPs, for example, OATP4A1, are expressed in multiple cells and organs. Many different tumor entities show an altered expression of OATPs. OATP1B1/OATP1B3 are downregulated in liver tumors, but highly expressed in cancers in the gastrointestinal tract, breast, prostate, and lung. Similarly, testis-specific OATP6A1 is expressed in cancers in the lung, brain, and bladder. Due to their presence in various cancer tissues and their limited expression in normal tissues, OATP1B1, OATP1B3, and OATP6A1 could be a target for tumor immunotherapy. Otherwise, high levels of ubiquitous expressed OATP4A1 are found in colorectal cancers and their metastases. Therefore, this OATP might serve as biomarkers for these tumors. Expression of OATP is regulated by nuclear receptors, inflammatory cytokines, tissue factors, and also posttranslational modifications of the proteins. Through these processes, the distribution of the transporter in the tissue will be altered, and a shift from the plasma membrane to cytoplasmic compartments is possible. It will modify OATP uptake properties and, subsequently, change intracellular concentrations of drugs, hormones, and various other OATP substrates. Therefore, screening tumors for OATP expression before therapy should lead to an OATP-targeted therapy with higher efficacy and decreased side effects.Keywords
This publication has 85 references indexed in Scilit:
- The Expression and Function of Organic Anion Transporting Polypeptides in Normal Tissues and in CancerAnnual Review of Pharmacology and Toxicology, 2012
- Environmental and Genetic Factors Affecting Transport of Imatinib by OATP1A2Clinical Pharmacology & Therapeutics, 2011
- Expression of SLCO Transport Genes in Castration-Resistant Prostate Cancer and Impact of Genetic Variation in SLCO1B3 and SLCO2B1 on Prostate Cancer OutcomesCancer Epidemiology, Biomarkers & Prevention, 2011
- Protein kinase C regulates the internalization and function of the human organic anion transporting polypeptide 1A2British Journal of Pharmacology, 2011
- Mesomelia-Synostoses Syndrome Results from Deletion of SULF1 and SLCO5A1 Genes at 8q13American Journal of Human Genetics, 2010
- Rapid Modulation of the Organic Anion Transporting Polypeptide 2B1 (OATP2B1, SLCO2B1) Function by Protein Kinase C-mediated Internalization*Published by Elsevier BV ,2010
- Overexpression of OATP1B3 Confers Apoptotic Resistance in Colon CancerCancer Research, 2008
- A polymorphism in a transporter of testosterone is a determinant of androgen independence in prostate cancerBJU International, 2008
- Effect of SLCO1B3 Haplotype on Testosterone Transport and Clinical Outcome in Caucasian Patients with Androgen-Independent Prostatic CancerClinical Cancer Research, 2008
- Expression and localization of prostaglandin transporter in Alzheimer disease brains and age-matched controlsJournal of Neuroimmunology, 2008